{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:50:06Z","timestamp":1761868206221,"version":"build-2065373602"},"reference-count":19,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Science Bulletin"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.scib.2021.03.001","type":"journal-article","created":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T22:26:30Z","timestamp":1615155990000},"page":"1491-1492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Placing old wine into new bottles: successful repurposing of bumetanide for treatment of autism spectrum disorder"],"prefix":"10.1016","volume":"66","author":[{"given":"Anthony G.","family":"Phillips","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.scib.2021.03.001_b0005","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nrd4489","article-title":"Securing the future of drug discovery for central nervous system disorders","volume":"13","author":"Andersen","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.scib.2021.03.001_b0010","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyu100","article-title":"Proceedings of the 2013 CINP Summit: innovative partnerships to accelerate CNS drug discovery for improved patient care","volume":"18","author":"Phillips","year":"2015","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.scib.2021.03.001_b0015","first-page":"12","article-title":"The death of CNS drug development: overstatement or omen?","volume":"3","author":"Riordan","year":"2011","journal-title":"J Clin Stud"},{"key":"10.1016\/j.scib.2021.03.001_b0020","first-page":"9","article-title":"The great neuro-pipeline \u2018brain drain\u2019 (and why big pharma hasn\u2019t given up on CNS disorders)","volume":"14","author":"Skripka-Serry","year":"2013","journal-title":"Drug Discov World"},{"key":"10.1016\/j.scib.2021.03.001_b0025","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1016\/j.neubiorev.2013.03.022","article-title":"Innovative solutions to novel drug development in mental health","volume":"37","author":"Insel","year":"2013","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.scib.2021.03.001_b0030","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.biopsych.2018.01.014","article-title":"Effective use of animal models for therapeutic development in psychiatric and substance use disorders","volume":"83","author":"Phillips","year":"2018","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.scib.2021.03.001_b0035","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/scientificamerican0410-44","article-title":"Faulty circuits","volume":"302","author":"Insel","year":"2010","journal-title":"Sci Am"},{"key":"10.1016\/j.scib.2021.03.001_b0040","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jad.2016.12.011","article-title":"Research domain criteria (RDoC) grows up: strengthening neurodevelopmental investigation within the RDoC framework","volume":"216","author":"Mittal","year":"2017","journal-title":"J Affec Disord"},{"key":"10.1016\/j.scib.2021.03.001_b0045","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nrd3628","article-title":"Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy","volume":"11","author":"Millan","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.scib.2021.03.001_b0050","doi-asserted-by":"crossref","unstructured":"Zhou M, Wang QQ, Zheng C, et al. Drug repurposing for opioid use disorders: integration of computational prediction, clinical corroboration, and mechanism of action analyses. Mol Psychiatry. 2021. https:\/\/doi.org\/10.1038\/s41380-020-01011-y.","DOI":"10.1038\/s41380-020-01011-y"},{"key":"10.1016\/j.scib.2021.03.001_b0055","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/j.drudis.2014.08.017","article-title":"Ketamine: repurposing and redefining a multifaceted drug","volume":"14","author":"Potter","year":"2014","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.scib.2021.03.001_b0060","unstructured":"Stewart, J. Spravato FDA Approval History. FDA History. 2020, https:\/\/www.drugs.com\/pro\/spravato.html."},{"key":"10.1016\/j.scib.2021.03.001_b0065","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.scib.2021.01.008","article-title":"Improved symptoms following bumetanide treatment in children aged 3\u22126 years with autism spectrum disorder: a randomized, double-blind, placebo-controlled trial","volume":"66","author":"Dai","year":"2021","journal-title":"Sci Bull"},{"key":"10.1016\/j.scib.2021.03.001_b0070","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1111\/j.1651-2227.2010.01933.x","article-title":"The diuretic bumetanide decreases autistic behaviour in five infants treated during 3 months with no side effects","volume":"99","author":"Lemonnier","year":"2010","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.scib.2021.03.001_b0075","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2012.124","article-title":"A randomised controlled trial of bumetanide in the treatment of autism in children","volume":"2","author":"Lemonnier","year":"2012","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.scib.2021.03.001_b0080","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-202092","article-title":"The effect of bumetanide treatment on the sensory behaviours of a young girl with Asperger syndrome","volume":"2014","author":"Grandgeorge","year":"2014","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.scib.2021.03.001_b0085","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/1362361313514141","article-title":"Improving emotional face perception in autism with diuretic bumetanide: a proof-of-concept behavioral and functional brain imaging pilot study","volume":"19","author":"Hadjikhani","year":"2015","journal-title":"Autism"},{"key":"10.1016\/j.scib.2021.03.001_b0090","article-title":"Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders","volume":"7","author":"Lemonnier","year":"2017","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.scib.2021.03.001_b0095","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41398-020-0692-2","article-title":"Symptom improvement in children with autism spectrum disorder following bumetanide administration is associated with decreased gaba\/glutamate ratios","volume":"10","author":"Zhang","year":"2020","journal-title":"Transl Psychiatry"}],"container-title":["Science Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S209592732100178X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S209592732100178X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:46:21Z","timestamp":1761867981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S209592732100178X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":19,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S209592732100178X"],"URL":"https:\/\/doi.org\/10.1016\/j.scib.2021.03.001","relation":{},"ISSN":["2095-9273"],"issn-type":[{"type":"print","value":"2095-9273"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Placing old wine into new bottles: successful repurposing of bumetanide for treatment of autism spectrum disorder","name":"articletitle","label":"Article Title"},{"value":"Science Bulletin","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.scib.2021.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Science China Press. Published by Elsevier B.V. and Science China Press. All rights reserved.","name":"copyright","label":"Copyright"}]}}